Abeona Therapeutics Inc. (ABEO)
Nasdaq: ABEO · Pharmaceutical Preparations · Cleveland, OH · filing with the SEC since 1995
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| Report filed | Mar 17, 2026 | Mar 20, 2025 | Mar 18, 2024 | Mar 29, 2023 | Mar 31, 2022 | Mar 24, 2021 | Mar 16, 2020 | Mar 18, 2019 | Mar 16, 2018 | Mar 30, 2017 |
| Revenue | 5,820 | · | 3,500 | 1,414 | 3,000 | 10,000 | · | 2,998 | 837 | 889 |
| For lenders | ||||||||||
| Interest and dividend income | 5,556 | 4,246 | 2,117 | 431 | 40 | · | · | · | · | · |
| Interest and investment income | · | · | · | · | · | · | · | 1,506 | 525 | 2,014 |
| Cost of revenue | 1,532 | · | · | · | · | · | · | · | · | · |
| Research and development | 26,812 | 34,360 | 31,091 | 28,965 | 38,726r | 30,139 | 48,566 | 38,698 | 16,989 | 10,655 |
| Selling, general and administrative | 65,031 | 29,851 | · | · | · | · | · | · | · | · |
| General and administrative | 65,031 | 29,851 | 19,004 | 17,256 | 21,644r | 23,779 | 20,705 | 20,106 | 10,943 | 13,290 |
| Total operating expenses | · | 64,211 | 50,635 | 52,329 | 92,836 | 91,420 | 77,090 | 61,164 | 28,673 | · |
| Total costs and expenses | 95,268 | 64,211 | · | · | · | · | · | 61,164 | 28,673 | 24,770 |
| Operating income | -89,448 | -64,211 | -47,135 | -50,915 | -89,836 | -81,420 | -77,090 | -58,166 | -27,836 | -23,881 |
| Interest expense | 3,740 | 4,208 | 418 | 736 | 3,656r | 4,115 | · | · | · | · |
| Total non-operating income (expense) | 410 | 1,194 | 2,943 | 141 | · | · | · | · | 517 | 2,008 |
| Income before income taxes | 71,283 | -63,734 | · | · | · | · | · | · | · | · |
| Income tax expense | 100 | · | · | · | · | · | · | 0 | 0 | 0 |
| Net income | 71,183 | -63,734 | -54,188 | -39,696 | -84,936 | -84,234 | -76,282 | -56,671 | -27,319 | -21,873 |
| Net income to common shareholders | · | -63,700 | -54,200r | -43,478 | -84,936 | · | · | · | · | -21,873 |
| Earnings per share, basic | 1.34 | -1.55 | -2.53 | -5.53 | -21.57 | · | · | · | · | · |
| Earnings per share, diluted | 1.01 | -1.55 | -2.53 | -5.53 | · | · | · | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -0.86 | -0.91 | -1.51 | -1.19 | -0.66 | -0.64 |
| Weighted average shares, basic | 52,952,917 | 41,048,206 | 21,380,476 | 7,861,515 | 3,937,676 | · | · | · | · | 34,180,253 |
| Weighted average shares, diluted | 66,135,821 | 41,048,206 | 21,380,476 | 7,861,515 | · | · | · | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 98,441,911 | 92,663,574 | 50,354,596 | 47,528,248 | 41,636,752 | 34,180,253 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-50 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:Revenues
us-gaap:SalesRevenueNetInterest and dividend income what its loans and securities earned
us-gaap:InterestIncomeOperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeNonoperatingCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:CostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted